{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T07:25:56Z","timestamp":1768289156131,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Intraductal papillary neoplasm of the bile duct (IPNB) is considered a pre-cancerous biliary lesion and\/or an early cancer lesion, although its classification remains unclear. The 2019 revised edition of the World Health Organization Classification of Tumors of the Digestive System proposed type 1 and type 2 as new classification categories, and meta-analyses and\/or multi-center cohort studies are beginning to be reported. However, treatment for IPNB recurrence and metastasis remains unclear.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 60-year-old man who was referred to our hospital after a suspected liver tumor was diagnosed using abdominal ultrasonography. Imaging findings revealed an irregularly shaped tumor in segment 5 (S5) of the liver (size 20\u2009mm). The S5 lesion was suspected as IPNB, and segmentectomy was performed. The pathological findings revealed invasive carcinoma derived from IPNB, and immunohistochemistry revealed positive expression of MUC1, MUC5AC, and MUC6, but negative expression of CDX2 and MUC2. At 9\u2009months after the surgery, computed tomography revealed a tumor in the right bile duct, which was diagnosed as liver recurrence of IPNB, and right hepatectomy was performed. The histopathological findings were the same as for the first resected specimen (i.e., IPNB). At 45\u2009months after the second surgery, computed tomography revealed nodules in both lungs, which were diagnosed as lung metastases from IPNB and resected in two separate procedures. The pathological findings were metastatic carcinoma from IPNB for both lung lesions. The patient is currently alive and undergoing adjuvant chemotherapy (S-1), which was initiated 64\u2009months after the first resection and 12\u2009months after resection of the lung metastases.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>We encountered a rare case of lung metastases from IPNB, which were diagnosed immunohistologically. Because IPNB is generally a slow-growing tumor, resection may be feasible for IPNB recurrence and\/or metastasis, which may be detected during long-term follow-up. Thus, even if resection is performed for primary IPNB, additional surgical treatment may be feasible in this setting.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12957-020-02054-9","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T11:02:54Z","timestamp":1603450974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lung metastases from intraductal papillary neoplasm of the bile duct: a case report"],"prefix":"10.1186","volume":"18","author":[{"given":"Rika","family":"Fujino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-5787","authenticated-orcid":false,"given":"Yoshihito","family":"Masuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Mashiko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Hirabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Nakagohri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"2054_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1053\/jhep.2001.28199","volume":"34","author":"TC Chen","year":"2001","unstructured":"Chen TC, Nakanuma Y, Zen Y, Chen MF, Jan YY, Yeh TS, et al. Intraductal papillary neoplasia of the liver associated with hepatolithiasis. Hepatology. 2001;34:651\u20138.","journal-title":"Hepatology."},{"key":"2054_CR2","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1097\/SLA.0000000000001426","volume":"263","author":"AN Gordon-Weeks","year":"2016","unstructured":"Gordon-Weeks AN, Jones K, Harriss E, Smith A, Silva M. Systematic review and meta-analysis of current experience in treating IPNB: clinical and pathological correlates. Ann Surg. 2016;263:656\u201363.","journal-title":"Ann Surg"},{"key":"2054_CR3","unstructured":"Nakamura Y, Bastruk O, Esposito I, Klimstra DS, Komuta M, Zen Y. Intraductal papillary neoplasm of the bile duct. In: WHO Classification of Tumors Editorial Board. Digestive System Tumors WHO Classification of Tumors. 5th ed: World Health Organization; 2019. p. 279\u201382."},{"key":"2054_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jhbp.532","volume":"25","author":"Y Nakanuma","year":"2018","unstructured":"Nakanuma Y, Jang KT, Fukushima N, Furukawa T, Hong SM, Kim H, et al. A statement by the Japan-Korea expert pathologists for future clinicopathological and molecular analyses toward consensus building of intraductal papillary neoplasm of the bile duct through several opinions at the present stage. J Hepatobiliary Pancreat Sci. 2018;25:181\u20137.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2054_CR5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1007\/s11605-019-04235-8","volume":"24","author":"Y You","year":"2019","unstructured":"You Y, Choi SH, Choi DW, Heo JS, Han IW, Jang KT, et al. Recurrence after resection for intraductal papillary neoplasm of bile duct (IPNB) according to tumor location. J Gastrointest Surg. 2019;24:804\u201312.","journal-title":"J Gastrointest Surg"},{"key":"2054_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s12029-018-00199-1","volume":"50","author":"P H\u00f6hn","year":"2019","unstructured":"H\u00f6hn P, Braumann C, Munding J, Tannapfel A, Uhl W, K\u00fcnzli BM. Outcome determining factors of intraductal papillary neoplasm of the biliary tract (IPNB)-a single center survey and analysis of current literature. J Gastrointest Cancer. 2019;50:160\u20139.","journal-title":"J Gastrointest Cancer"},{"key":"2054_CR7","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3748\/wjg.v26.i3.366","volume":"26","author":"NH Nam","year":"2020","unstructured":"Nam NH, Taura K, Kanai M, Fukuyama K, Uza N, Maeda H, et al. Unexpected metastasis of intraductal papillary neoplasm of the bile duct without an invasive component to the brain and lungs: a case report. World J Gastroenterol. 2020;26:366\u201374.","journal-title":"World J Gastroenterol"},{"key":"2054_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jtho.2018.12.005","volume":"14","author":"Y Yatabe","year":"2019","unstructured":"Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, et al. Best practices recommendations for diagnostic immunohistochemistry in lung cancer. J Thorac Oncol. 2019;14:377\u2013407.","journal-title":"J Thorac Oncol"},{"key":"2054_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.5009\/gnl18476","volume":"13","author":"Y Nakanuma","year":"2019","unstructured":"Nakanuma Y, Kakuda Y, Uesaka K. Characterization of intraductal papillary neoplasm of the bile duct with respect to the histopathologic similarities to pancreatic intraductal papillary mucinous neoplasm. Gut Liver. 2019;13:617\u201327.","journal-title":"Gut Liver"},{"key":"2054_CR10","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.ejso.2018.10.532","volume":"45","author":"F Harada","year":"2019","unstructured":"Harada F, Matsuyama R, Mori R, Kumamoto T, Morioka D, Taguri M, et al. Outcomes of surgery for 2010 WHO classification-based intraductal papillary neoplasm of the bile duct: case-control study of a single Japanese institution\u2019s experience with special attention to mucin expression patterns. Eur J Surg Oncol. 2019;45:761\u20138.","journal-title":"Eur J Surg Oncol"},{"key":"2054_CR11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/jhbp.23","volume":"21","author":"K Kubota","year":"2014","unstructured":"Kubota K, Nakanuma Y, Kondo F, Hachiya H, Miyazaki M, Nagino M, et al. Clinicopathological features and prognosis of mucin-producing bile duct tumor and mucinous cystic tumor of the liver: a multi-institutional study by the Japan Biliary Association. J Hepatobiliary Pancreat Sci. 2014;21:176\u201385.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2054_CR12","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.21873\/anticanres.13635","volume":"39","author":"T Sato","year":"2019","unstructured":"Sato T, Hisaka T, Sakai H, Ishikawa H, Kawahara R, Goto Y, et al. Clinicopathological study of resections of intraductal papillary neoplasm of the bile duct. Anticancer Res. 2019;39:4569\u201373.","journal-title":"Anticancer Res"},{"key":"2054_CR13","first-page":"1753","volume":"19","author":"M Kinoshita","year":"2018","unstructured":"Kinoshita M, Takemura S, Tanaka S, Shinkawa H, Hamano G, Ito T, et al. The clinical significance of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with occupational cholangiocarcinoma. Asian Pac J Cancer Prev. 2018;19:1753\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"key":"2054_CR14","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.21873\/anticanres.12645","volume":"38","author":"Y Ikeno","year":"2018","unstructured":"Ikeno Y, Seo S, Yamamoto G, Nakamoto Y, Uemoto Y, Fuji H, et al. Usefulness of preoperative 18-FDG-PET in detecting invasive intraductal papillary neoplasm of the bile duct. Anticancer Res. 2018;38:3677\u201382.","journal-title":"Anticancer Res"},{"key":"2054_CR15","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/s12149-012-0607-2","volume":"26","author":"A Dong","year":"2012","unstructured":"Dong A, Dong H, Zhang L, Zuo C. F-18 FDG uptake in borderline intraductal papillary neoplasms of the bile duct. Ann Nucl Med. 2012;26:594\u20138.","journal-title":"Ann Nucl Med"},{"key":"2054_CR16","first-page":"231","volume":"26","author":"Y Yoshida","year":"2012","unstructured":"Yoshida Y, Ajiki T, Ueno K, Ohtsubo I, Murakami S, Shinozaki K. Advanced intraductal papillary neoplasm of bile duct (IPNB) in a young female with metastases to lymph nodes and ovary. Tando. 2012;26:231\u20136.","journal-title":"Tando"},{"key":"2054_CR17","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/hep.25786","volume":"56","author":"FG Rocha","year":"2012","unstructured":"Rocha FG, Lee H, Katabi N, DeMatteo RP, Fong Y, D\u2019Angelica MI, et al. Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology. 2012;56:1352\u201360.","journal-title":"Hepatology."},{"key":"2054_CR18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s00534-009-0153-z","volume":"17","author":"T Tsuyuguchi","year":"2010","unstructured":"Tsuyuguchi T, Sakai Y, Sugiyama H, Miyakawa K, Ishihara T, Ohtsuka M, et al. Endoscopic diagnosis of intraductal papillary mucinous neoplasm of the bile duct. J Hepatobiliary Pancreat Sci. 2010;17:230\u20135.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2054_CR19","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3109\/00365521.2012.722672","volume":"48","author":"MA D'souza","year":"2013","unstructured":"D'souza MA, Isaksson B, L\u00f6hr M, Enochsson L, Swahn F, Lundell L, et al. The clinicopathological spectrum and management of intraductal papillary mucinous neoplasm of the bile duct (IPMN-B). Scand J Gastroenterol. 2013;48:473\u20139.","journal-title":"Scand J Gastroenterol"},{"key":"2054_CR20","doi-asserted-by":"crossref","unstructured":"Kim JR, Jang KT, Jang JY, Lee K, Kim JH, Kim H, et al. Clinicopathologic analysis of intraductal papillary neoplasm of bile duct: Korean multicenter cohort study. HPB (Oxford). 2019.","DOI":"10.1016\/j.hpb.2018.06.273"},{"key":"2054_CR21","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.3346\/jkms.2018.33.e266","volume":"33","author":"JR Kim","year":"2018","unstructured":"Kim JR, Lee KB, Kwon W, Kim E, Kim SW, Jang JY. Comparison of the Clinicopathologic characteristics of intraductal papillary neoplasm of the bile duct according to morphological and anatomical classifications. J Korean Med Sci. 2018;33:e266.","journal-title":"J Korean Med Sci"},{"key":"2054_CR22","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.3748\/wjg.v25.i36.5569","volume":"25","author":"T Hasebe","year":"2019","unstructured":"Hasebe T, Sawada K, Hayashi H, Nakajima S, Takahashi H, Hagiwara M, et al. Long-term growth of intrahepatic papillary neoplasms: a case report. World J Gastroenterol. 2019;25:5569\u201377.","journal-title":"World J Gastroenterol"},{"key":"2054_CR23","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1007\/s00268-017-3877-y","volume":"41","author":"M Yamada","year":"2017","unstructured":"Yamada M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, et al. Pulmonary metastasis after resection of cholangiocarcinoma: incidence, resectability, and survival. World J Surg. 2017;41:1550\u20137.","journal-title":"World J Surg"},{"key":"2054_CR24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1245\/s10434-010-1325-4","volume":"18","author":"Y Murakami","year":"2011","unstructured":"Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol. 2011;18:651\u20138.","journal-title":"Ann Surg Oncol"},{"key":"2054_CR25","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1245\/s10434-008-0227-1","volume":"16","author":"S Yedibela","year":"2009","unstructured":"Yedibela S, Demir R, Zhang W, Meyer T, Hohenberger W, Sch\u00f6nleben F. Surgical treatment of mass-forming intrahepatic cholangiocarcinoma: an 11-year Western single-center experience in 107 patients. Ann Surg Oncol. 2009;16:404\u201312.","journal-title":"Ann Surg Oncol"},{"key":"2054_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/01.sla.0000160817.94472.fd","volume":"241","author":"WR Jarnagin","year":"2005","unstructured":"Jarnagin WR, Bowne W, Klimstra DS, Ben-Porat L, Roggin K, Cymes K, et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg. 2005;241:703\u201312 discussion 712-4.","journal-title":"Ann Surg"},{"key":"2054_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/bjs.4366","volume":"91","author":"Y Tajima","year":"2004","unstructured":"Tajima Y, Kuroki T, Fukuda K, Tsuneoka N, Furui J, Kanematsu T. An intraductal papillary component is associated with prolonged survival after hepatic resection for intrahepatic cholangiocarcinoma. Br J Surg. 2004;91:99\u2013104. https:\/\/doi.org\/10.1002\/bjs.4366.","journal-title":"Br J Surg"},{"key":"2054_CR28","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. BILCAP study group. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomized, controlled, multicenter, phase 3 study. Lancet Oncol. 2019;20:663\u201373.","journal-title":"Lancet Oncol"},{"key":"2054_CR29","doi-asserted-by":"publisher","first-page":"e14013","DOI":"10.1097\/MD.0000000000014013","volume":"98","author":"KW Ma","year":"2019","unstructured":"Ma KW, Cheung TT, Leung B, She BWH, Chok KSH, Chan ACY, et al. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: a meta-analysis. Medicine (Baltimore). 2019;98:e14013.","journal-title":"Medicine (Baltimore)"},{"key":"2054_CR30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00535-018-1518-3","volume":"54","author":"Y Suzuki","year":"2019","unstructured":"Suzuki Y, Kan M, Kimura G, Umemoto K, Watanabe K, Sasaki M, et al. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy. J Gastroenterol. 2019;54:281\u201390.","journal-title":"J Gastroenterol"},{"key":"2054_CR31","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","volume":"5","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5:824\u201330.","journal-title":"JAMA Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-020-02054-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-020-02054-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-020-02054-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T19:47:41Z","timestamp":1634932061000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-020-02054-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2054"],"URL":"https:\/\/doi.org\/10.1186\/s12957-020-02054-9","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]},"assertion":[{"value":"14 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the hospital\u2019s review board of Tokai University School of Medicine (approval no: TOKAI 19R-026). Written informed consent was obtained from the patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"271"}}